UC San Diego

UC San Diego Previously Published Works

Title

Using postoperative pain trajectories to define the role of regional analgesia in personalised pain medicine.

Permalink

<https://escholarship.org/uc/item/94j7312k>

Journal

Anaesthesia, 76(2)

ISSN

0003-2409

Authors

Mariano, ER
El-Boghdadly, K
Ilfeld, BM

Publication Date

2021-02-01

DOI

10.1111/anae.15067

Peer reviewed

Editorial

Using postoperative pain trajectories to define the role of regional analgesia in personalised pain medicine

E. R. Mariano,^{1,2} K. El-Boghdady^{3,4} and B. M. Ilfeld^{5,6}

1 Professor, Department of Anesthesiology, Peri-operative and Pain Medicine, Stanford University School of Medicine, Stanford, CA, USA

2 Chief, Anesthesiology and Peri-operative Care Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA

3 Consultant, Department of Anaesthesia, Guy's and St Thomas' NHS Foundation Trust, London, UK

4 Honorary Senior Lecturer, King's College London, UK

5 Professor, In Residence, Department of Anesthesiology, University of California, San Diego, School of Medicine, San Diego, CA, USA

6 Outcomes Research Consortium, Cleveland, OH, USA

Correspondence to: E. Mariano

Email: emariano@stanford.edu

Accepted: 24 March 2020

Keywords: acute pain; nerve block; postoperative pain; regional anaesthesia; surgery; trajectory

Twitter: @EMARIANOMD; @elboghdady; @BrianIlfeld

Who decides how long a regional block should last? The short answer is that the anaesthetist does. In routine clinical practice, the anaesthetist usually decides whether or not to offer a regional block and, if so, whether the block will be a single-injection (with or without adjuncts) or continuous peripheral nerve block. While in an ideal world this decision would be influenced by data, it is typically governed by several factors, not the least of which are assumptions made by the anaesthetist. The anaesthetist chooses a regional block option that may last 1, 2 or maybe 3 days depending on technique and pharmacologic agents, assuming that this duration will be sufficient, but without much data to support this assumption. Even recent initiatives that have focused on developing procedure-specific pain management protocols have lacked these data [1]. This is, in essence, putting the proverbial cart before the horse.

What if we had these data? What would we do differently? Very few studies have specifically explored the concept of pain trajectories after surgery. If we knew the typical pain trajectories and patterns of postoperative pain regression and resolution for common surgical procedures, the data could guide our approaches to regional analgesia. We need these data to put the horse back in front of the cart.

Exploring postoperative pain trajectories

Previous efficacy studies of continuous peripheral nerve block for various surgical procedures included placebo groups [2–5] which give us an opportunity to look more closely at the variability in 'normal' postoperative pain trajectories. These studies were performed primarily at a single institution under rigorous triple-blinded protocols. All study participants received an initial block with local anaesthesia but were randomly assigned to remain on local anaesthetic or change to saline continuous peripheral nerve block infusions by the morning after surgery. Using these previously published data, we have mapped the worst pain trajectories for the placebo groups from these four studies involving: total knee arthroplasty; total hip arthroplasty; mastectomy; and shoulder arthroscopy [2–5] (Fig. 1). Both studies involving total knee and hip arthroplasty measured pain daily through postoperative day six, while the mastectomy and shoulder arthroscopy studies evaluations were either on discrete days (one, four and eight) or through day three, respectively. While there are limitations to our ability to generalise the results of randomised clinical trials, viewing

Figure 1 Mean worst pain scores for four surgical procedures: total knee arthroplasty; total hip arthroplasty; mastectomy; and shoulder arthroscopy. Error bars represent 95%CI.

these data confirms that the postoperative pain trajectory can differ greatly from one procedure to the next.

Interestingly, the pain trajectory for total knee arthroplasty (Fig. 1) essentially matches the trajectory reported by Lavand'homme et al. of knee arthroplasty patients who do not go on to develop chronic pain [6]. From Lavand'homme et al.'s study sample, we know that the average maximal pain score after total knee arthroplasty

does not consistently fall below four on a numeric rating scale (NRS; 0, no pain; 10, highest pain possible) until approximately postoperative day seven [6]. It is even longer for patients who go on to develop persistent post-surgical pain. Although we cannot extrapolate these data to every surgical population, we can conclude that any single-injection regional analgesic for total knee arthroplasty in all likelihood does not last long enough. As expectations grow

for shorter lengths of stay, including outpatient total knee arthroplasty [7], the fact that nearly all of the postoperative recovery will occur at home demands an appropriate regional analgesic strategy that is matched to the anticipated trajectory of pain resolution and can be easily managed on an ambulatory basis. By applying the right duration of regional analgesia to the right surgical population, we may finally be able to move beyond immediate postoperative pain and 24-h opioid use as primary outcomes for regional anaesthesia research studies and aim to improve more meaningful outcomes such as the incidence of persistent post-surgical pain, long-term functional recovery and chronic opioid use.

We are very aware of the opioid epidemic primarily affecting North America [8] and the role of surgery in introducing patients to opioids for the first time; some of these patients will go on to become chronic opioid users [9]. We acknowledge that regional analgesia is rarely the only pain management modality for surgical patients, and postoperative pain after every surgery should be managed using a multimodal approach to minimise opioid use [10]. However, regional analgesia remains the only acute pain intervention that can specifically target the surgical site. Postoperative pain remains one of the patients' top concerns when undergoing elective surgery [11]. Poorly treated pain can limit patients' functional ability in the postoperative period [12] and early postoperative rehabilitation has been associated with improvements in longer term functional outcomes [13].

Based on our data visualisation a 3-day continuous peripheral nerve block infusion may be reasonable for total hip arthroplasty, mastectomy and outpatient shoulder arthroscopy. Through the study of postoperative pain trajectories, we can identify different patterns of pain resolution among patient groups and surgical procedures that can help us design personalised pain medicine plans specific to these procedures. Of note, none of the four surgical procedures represented in the figure seem appropriate for a traditional single-injection block.

Currently available long-acting local anaesthetics (e.g. bupivacaine, levobupivacaine and ropivacaine) generally provide analgesia of similar duration but less than 24 h [14–17].

Several different pharmacologic adjuvants have been investigated for their potential to extend single-injection peripheral nerve block duration when added to local anaesthetic solutions. These include, but are not limited to: adrenaline [18]; buprenorphine [19, 20]; alpha-2 agonists such as clonidine [21, 22] and dexmedetomidine [23–25]; and dexamethasone [26, 27]. In general, most studies of

single-injection nerve blocks with adjuvants fail to demonstrate a reliable duration beyond one day postoperatively. Additionally, nearly all adjuvants have not been specifically tested and approved for nerve blocks (i.e. 'off-label' use) by national regulatory agencies like the Food and Drug Administration (FDA) in the US or the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK. Liposomal bupivacaine, an extended release formulation, has been studied for over 20 years [28] as a means to prolong nerve blockade, but has only been FDA-approved in the US for two regional anaesthetic indications: transversus abdominis plane blocks (considered a field block) and interscalene brachial plexus blocks for shoulder surgery. It has not secured approval from the MHRA or the European Medicines Agency to date.

The greatest limitation to this 'one-size-fits-all' regional analgesia in the form of long-acting single-injection blocks is that they cannot be adjusted. They cannot be decreased in the event of an insensate extremity, nor can they be extended to increase the duration of analgesia. Unfortunately, we cannot reliably predict which patients will need longer blocks in the form of continuous peripheral nerve block before surgery. When patients exhibit greater than expected pain after block resolution, it is too late.

Continuous peripheral nerve block is the only technique currently available that enables titration of local anaesthetic solutions to a peripheral nerve or fascial plane [29]. Using an electronic infusion pump with an external reservoir, the infusion duration is typically limited by the amount of local anaesthetic a patient is able to carry, and single-use elastomeric pumps with an internal reservoir for local anaesthetic rarely last beyond 3 days without replacement [29], which may not be long enough for certain surgical procedures like knee arthroplasty. Based on one systematic review and meta-analysis, patients who receive continuous peripheral nerve block: report lower maximal pain scores during infusion; experience less nausea; have decreased opioid dose requirements; sleep better; and are more satisfied with pain management for the first 2 days after surgery, when compared with single-injection blocks [30]. The differences in maximal pain scores were generally between 1–2 on an 11-point numeric rating scale: effect size -1.29 (95%CI -2.19 to -0.40) on postoperative day 0; -1.87 (95%CI -2.44 to -1.31) on postoperative day 1; and -2.03 (95%CI -2.78 to -1.29) on postoperative day 2 [30]. Unfortunately, the studies included in this meta-analysis utilised only short-term infusions, and the benefits did not persist after catheter removal [30]. These findings suggest that there is still much more work to do in terms

of determining the optimal procedure-specific continuous peripheral nerve block regimen and matching analgesia to pain trajectory. Besides continuous peripheral nerve block, few other therapies in the realm of acute pain medicine offer the potential combination of titratability and flexible duration [31]. Despite more than a decade of supportive data, adoption of continuous peripheral nerve block is still far from universal. A common obstacle to implementation of continuous peripheral nerve block reported by study participants is time pressure; additional barriers include lack of surgeon support and inadequate skills [32].

As a specialty, anaesthesia has to take the lead in defining personalised pain medicine after surgery. Future research into identifying the phenotypes and genotypes associated with greater-than-expected acute pain and persistent post-surgical pain will help design tailored peri-operative pain management plans. Observational studies of pain trajectories for all of the common surgical procedures, from populations of patients and not just randomised clinical trials with narrow inclusion/exclusion criteria, can generate much-needed data that will serve as the basis for prescribing the right regimen and duration of regional analgesic techniques. Moreover, the long-term benefits of personalised pain medicine will need to be rigorously examined. Finally, future advances in technology for continuous peripheral nerve block delivery systems, neuromodulation or new pharmacologic agents for nerve blockade may hold the key to maximising the role of regional analgesia in peri-operative pain management for every patient.

Acknowledgements

This work was supported with resources and the use of facilities at the Veterans Affairs Palo Alto Healthcare System (Palo Alto, CA, USA). The contents do not represent the views of the Department of Veterans Affairs or the US Government. KE is an Editor of *Anaesthesia* and has received consulting fees from Ambu (Copenhagen, Denmark), travel and research support from Fisher and Paykel Healthcare Ltd. (Auckland, NZ), and educational funding from GE Healthcare (London, UK). BI has received research funding from the U.S. Department of Defense. Opinions, interpretations, conclusions and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense. BI has received funding and product for other research projects from Myoscience (Fremont, CA, USA), Epimed (Farmers Branch, TX, USA), Infutronics (Natick, MA, USA), Ferrosan Medical (Søborg, Denmark), SPR Therapeutics (Cleveland, OH,

USA) and Heron Pharmaceuticals (San Diego, CA, USA). None of these companies had any input into the conception or preparation of this manuscript. No other competing interests declared.

References

1. Joshi GP, Van de Velde M, Kehlet H. Development of evidence-based recommendations for procedure-specific pain management: PROSPECT methodology. *Anaesthesia* 2019; **74**: 1298–304.
2. Ilfeld BM, Madison SJ, Suresh PJ, et al. Treatment of postmastectomy pain with ambulatory continuous paravertebral nerve blocks: a randomized, triple-masked, placebo-controlled study. *Regional Anesthesia and Pain Medicine* 2014; **39**: 89–96.
3. Mariano ER, Afra R, Loland VJ, et al. Continuous interscalene brachial plexus block via an ultrasound-guided posterior approach: a randomized, triple-masked, placebo-controlled study. *Anesthesia and Analgesia* 2009; **108**: 1688–94.
4. Ilfeld BM, Le LT, Meyer RS, et al. Ambulatory continuous femoral nerve blocks decrease time to discharge readiness after tricompartiment total knee arthroplasty: a randomized, triple-masked, placebo-controlled study. *Anesthesiology* 2008; **108**: 703–13.
5. Ilfeld BM, Ball ST, Gearen PF, et al. Ambulatory continuous posterior lumbar plexus nerve blocks after hip arthroplasty: a dual-center, randomized, triple-masked, placebo-controlled trial. *Anesthesiology* 2008; **109**: 491–501.
6. Lavand'homme PM, Grosu I, France MN, Thienpont E. Pain trajectories identify patients at risk of persistent pain after knee arthroplasty: an observational study. *Clinical Orthopaedic Related Research* 2014; **472**: 1409–15.
7. Li J, Rubin LE, Mariano ER. Essential elements of an outpatient total joint replacement programme. *Current Opinions in Anaesthesiology* 2019; **32**: 643–8.
8. Alam A, Juurlink DN. The prescription opioid epidemic: an overview for anesthesiologists. *Canadian Journal of Anesthesia* 2016; **63**: 61–8.
9. Brummett CM, Waljee JF, Goesling J, et al. New persistent opioid use after minor and major surgical procedures in US adults. *Journal of the American Medical Association Surgery* 2017; **152**: e170504.
10. Kandarian BS, Elkassabany NM, Tamboli M, Mariano ER. Updates on multimodal analgesia and regional anesthesia for total knee arthroplasty patients. *Best Practice and Research in Clinical Anaesthesiology* 2019; **33**: 111–23.
11. Macario A, Weinger M, Carney S, Kim A. Which clinical anesthesia outcomes are important to avoid? The perspective of patients. *Anesthesia and Analgesia* 1999; **89**: 652–8.
12. Holm B, Kristensen MT, Myhrmann L, et al. The role of pain for early rehabilitation in fast track total knee arthroplasty. *Disability and Rehabilitation* 2010; **32**: 300–6.
13. Munin MC, Rudy TE, Glynn NW, Crossett LS, Rubash HE. Early inpatient rehabilitation after elective hip and knee arthroplasty. *Journal of the American Medical Association* 1998; **279**: 847–52.
14. Casati A, Borghi B, Fanelli G, et al. A double-blinded, randomized comparison of either 0.5% levobupivacaine or 0.5% ropivacaine for sciatic nerve block. *Anesthesia and Analgesia* 2002; **94**: 987–90.
15. Hickey R, Hoffman J, Ramamurthy S. A comparison of ropivacaine 0.5% and bupivacaine 0.5% for brachial plexus block. *Anesthesiology* 1991; **74**: 639–42.
16. Klein SM, Greengrass RA, Steele SM, et al. A comparison of 0.5% bupivacaine, 0.5% ropivacaine, and 0.75% ropivacaine for interscalene brachial plexus block. *Anesthesia and Analgesia* 1998; **87**: 1316–9.

17. Fanelli G, Casati A, Beccaria P, et al. A double-blind comparison of ropivacaine, bupivacaine, and mepivacaine during sciatic and femoral nerve blockade. *Anesthesia and Analgesia* 1998; **87**: 597–600.
18. Weber A, Fournier R, Van Gessel E, Riand N, Gamulin Z. Epinephrine does not prolong the analgesia of 20 mL ropivacaine 0.5% or 0.2% in a femoral three-in-one block. *Anesthesia and Analgesia* 2001; **93**: 1327–31.
19. Candido KD, Hennes J, Gonzalez S, et al. Buprenorphine enhances and prolongs the postoperative analgesic effect of bupivacaine in patients receiving infragluteal sciatic nerve block. *Anesthesiology* 2010; **113**: 1419–26.
20. Candido KD, Franco CD, Khan MA, Winnie AP, Raja DS. Buprenorphine added to the local anesthetic for brachial plexus block to provide postoperative analgesia in outpatients. *Regional Anesthesia and Pain Medicine* 2001; **26**: 352–6.
21. McCartney CJ, Duggan E, Apatu E. Should we add clonidine to local anesthetic for peripheral nerve blockade? A qualitative systematic review of the literature. *Regional Anesthesia and Pain Medicine* 2007; **32**: 330–8.
22. Popping DM, Elia N, Marret E, Wenk M, Tramer MR. Clonidine as an adjuvant to local anesthetics for peripheral nerve and plexus blocks: a meta-analysis of randomized trials. *Anesthesiology* 2009; **111**: 406–15.
23. Agarwal S, Aggarwal R, Gupta P. Dexmedetomidine prolongs the effect of bupivacaine in supraclavicular brachial plexus block. *Journal of Anaesthesiology and Clinical Pharmacology* 2014; **30**: 36–40.
24. Song JH, Shim HY, Lee TJ, et al. Comparison of dexmedetomidine and epinephrine as an adjuvant to 1% mepivacaine in brachial plexus block. *Korean Journal of Anesthesiology* 2014; **66**: 283–9.
25. Singh AP, Mahindra M, Gupta R, Bajwa SJ. Dexmedetomidine as an adjuvant to levobupivacaine in supraclavicular brachial plexus block: A novel anesthetic approach. *Anesthesia Essays and Research* 2016; **10**: 414–9.
26. Aliste J, Leurcharusmee P, Engsusophon P, et al. A randomized comparison between intravenous and perineural dexamethasone for ultrasound-guided axillary block. *Canadian Journal of Anesthesia* 2017; **64**: 29–36.
27. Leurcharusmee P, Aliste J, Van Zundert TC, et al. A multicenter randomized comparison between intravenous and perineural dexamethasone for ultrasound-guided infraclavicular block. *Regional Anesthesia and Pain Medicine* 2016; **41**: 328–33.
28. Boogaerts J, Lafont N, Donnay M, Luo H, Legros FJ. Motor blockade and absence of local nerve toxicity induced by liposomal bupivacaine injected into the brachial plexus of rabbits. *Acta Anaesthesiologica Belgica* 1995; **46**: 19–24.
29. Ilfeld BM. Continuous peripheral nerve blocks: a review of the published evidence. *Anesthesia and Analgesia* 2011; **113**: 904–25.
30. Bingham AE, Fu R, Horn JL, Abrahams MS. Continuous peripheral nerve block compared with single-injection peripheral nerve block: a systematic review and meta-analysis of randomized controlled trials. *Regional Anesthesia and Pain Medicine* 2012; **37**: 583–94.
31. Ilfeld BM, Ball ST, Gabriel RA, et al. A feasibility study of percutaneous peripheral nerve stimulation for the treatment of postoperative pain following total knee arthroplasty. *Neuromodulation* 2018.
32. Mariano ER, Harrison TK, Kim TE, et al. Evaluation of a standardized program for training practicing anesthesiologists in ultrasound-guided regional anesthesia skills. *Journal of Ultrasound in Medicine* 2015; **34**: 1883–93.